Botulinum Toxin A for Herpes Labialis

Herpes Labialis Clinical Trial

Official title:

A Double-Blind, Randomized, Placebo Controlled, Crossover Study to Assess the Safety and Efficacy of Botulinum Toxin A Injections as a Preventative Measure for Herpes Labialis.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01225341
• Other study ID #: HSV-BOT-01-09
• Status: Terminated
• Phase: N/A
• Start date: August 2010
• Est. completion date: June 2012

Study information

• Verified date: November 2020
• Source: DeNova Research
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine the efficacy and safety of Botulinum Toxin Type A as a preventative measure for Herpes Labialis.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 20
• Est. completion date: June 2012
• Est. primary completion date: May 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 64 Years

Eligibility

Inclusion Criteria:

• Males or females between the ages of 18 and 64.

• Have herpes simplex virus 1 (HSV-1) with between 2-6 herpes labialis recurrences per year.

• Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study.

• Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e.g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:

• postmenopausal for at least 12 months prior to study drug administration

• without a uterus and/or both ovaries

• has had a bilateral tubal ligation for at least 6 months prior to study drug administration.

• absence of an other physical condition according to the PI's discretion

• Willingness and ability to provide written photo consent and adherence to photography procedures (i.e., removal of jewelry and makeup).

• Willingness and ability to provide written informed consent prior to performance of any study related procedure.

Exclusion Criteria:

• Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control.

• Subjects with a known allergy or sensitivity to any component of the study medications or anesthesia.

• Active recurrence of herpes labialis.

• Botulinum toxin to the lower 1/3 of the face with the past 6 months.

• Significant concurrent illness such as diabetes, epilepsy, lupus, or congestive heart failure.

• Concurrent skin condition affecting area to be treated.

• Prior surgery on the area to be treated within 3 months of initial treatment or during the study.

• History or evidence of keloids or hypertrophic scarring.

• Current use of antivirals for the treatment of herpes labialis within 2 weeks prior to initiation of treatment (e.g., acyclovir, valaciclovir, famciclovir, and penciclovir).

• Topical use of over-the-counter medications for the treatment or prevention of HSV-1 (e.g., Abreva).

• Subjects currently using aminoglycoside antibiotics, curare-like agents or other agents that might interfere with neuromuscular function.

• Subjects with a diagnosis of Myasthenia Gravis, Eaton-Lambert Syndrome, Amyotrophic Lateral Sclerosis, or any other disease that might interfere with neuromuscular function or current facial palsy.

• Current history of chronic drug or alcohol abuse.

• Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication.

• Subjects who, in the Investigator's opinion, have a history of poor cooperation, non-compliance with medical treatment or unreliability.

• Enrollment in any active study involving the use of investigational devices or drugs.

Related Conditions & MeSH terms

• Herpes Labialis

Intervention

Drug:
• onabotulinumtoxinA
Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.

Other:
• Bacteriostatic normal saline
Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.

Locations

Country	Name	City	State
United States	DeNova Research	Chicago	Illinois

Sponsors (2)

Lead Sponsor	Collaborator
DeNova Research	Allergan

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Measurement of Recurrence and Duration of Herpes Labialis Lesions	Days between last injection and outbreak onset & Days between onset and recurrence	12 months
Secondary	Measurement of Lesion Size	Lesions will be measured in millimeters across the maximal lesion length in mm	12 months
Secondary	Pain Assessment	Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to the Visual Analog Scale for pain (VAS) by placing a straight line intersecting the pain line. The scale will be 10 cm long and the distance from start to mark will be measured in millimeters.; Score range is 0-10. Scores closer to 0 signify lower pain levels and scores closer to 10 signify high pain levels	During outbreak
Secondary	Symptom Evaluation	Each day of a recurrence of herpes labialis, the subject will document his/her pain level in the diary according to a 4-point scale ((0) none, (1) mild, (2) moderate, (3) severe).; Scores closer to 0 indicate a more favorable outcome.	During outbreak

External Links

•   DeNova Research